Gynecologic Cancers: Basic Sciences, Clinical and Therapeutic Perspectives PDF
Preview Gynecologic Cancers: Basic Sciences, Clinical and Therapeutic Perspectives
Gynecologic Cancers Basic Sciences, Clinical and Therapeutic Perspectives Edited by Samir A. Farghaly Gynecologic Cancers: Basic Sciences, Clinical and Therapeutic Perspectives Edited by Samir A. Farghaly Stole src from http://avxhome.se/blogs/exLib/ Published by ExLi4EvA Copyright © 2016 All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. As for readers, this license allows users to download, copy and build upon published chapters even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Publishing Process Manager Technical Editor AvE4EvA MuViMix Records Cover Designer Спизжено у ExLib: avxhome.se/blogs/exLib First published March 02, 2016 Stole src from http://avxhome.se/blogs/exLib: Спизжено у ExLib: avxhome.se/blogs/exLib ISBN-10: 953-51-4278-X ISBN-13: 978-953-51-4278-2 C ontents Preface Chapter 1 Role of BRCA1 in Breast Cancer Metastasis by S. Satheesh Kumar, K.H. Sreelatha, Revathy Nadhan and Priya Srinivas Chapter 2 Interplay of Epigenetics with Gynecological Cancer by Coralia Bleotu, Demetra Socolov, Mariana Anton, Anca Botezatu, Adriana Plesa, Iulia Virginia Iancu, Lorelei Irina Brasoveanu, Gabriela Anton and Carmen Cristina Diaconu Chapter 3 Antiangiogenic Therapy in Epithelial Ovarian Cancer by M.A. Alonso Bermejo, L. Rey Iglesias , M.E. Pérez López, A. Fernández Montes and J. García Mata Chapter 4 Peritonectomy Procedures and HIPEC for Peritoneal Metastasis from Ovarian Cancer by Angelo Di Giorgio, Daniele Biacchi, Antonio Ciardi, Alessio Impagnatiello, Maurizio Cardi, Simone Sibio, Bianca Sollazzo, Joseph Maher Fouad Atta, Giuseppe Naso, Fabio Accarpio and Paolo Sammartino Chapter 5 Individualized Novel Therapies for Patients with Tumor Suppressor Genes BRCA1 and BRCA2 Mutated Epithelial Ovarian Cancer by Sandra García-Nieto, Carmen Guillén-Ponce, Carmen Alonso, María- Carmen Rodríguez-Soriano, María-Luz Pombo, Earl Julie and Samir A. Farghaly Chapter 6 Ovarian Cancer Research in the Post Genomic Era — Challenges and Opportunities by Alicia A. Goyeneche and Carlos M. Telleria VI Contents Chapter 7 Analysing Molecular Mechanism Related to Therapy- Resistance in In-vitro Models of Ovarian Cancer by Jens C. Hahne, Arnd Honig, Jörg B. Engel, Andrea Lampis and Nicola Valeri Chapter 8 Recurrent Ovarian Cancer — Basic Knowledge, Current Management, and Future Directions by Bernardo L. Rapoport Chapter 9 Management of Ovarian Cancer — Is There a Role for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? by Melissa Ching Ching Teo and Grace Hwei Ching Tan Chapter 10 Anti-Angiogenic and Anti-Cancer Effects by Targeting the Protein Kinase G Type-Iα (PKG-Iα) Signaling Pathway and its Downstream Effects on Expression of Inhibitor of Apoptosis Proteins, C-IAP1, Livin and Survivin by Janica C. Wong, Priyatham Gorjala, Benjamin Costantino and Ronald R. Fiscus Chapter 11 Cancer of the Vulva — A Review by Fernando Anschau and Manoel Afonso Guimarães Gonçalves Chapter 12 Robotic Surgery in the Management of Endometrial Cancer by Mark Williams, John Villeneuve and Bernice Robinson-Bennett Chapter 13 Cervical Cancer in Human Immunodeficiency Virus (HIV) Positive Patients by Atara Ntekim Chapter 14 Sentinel Lymph Node Detection in Early Stage Cervical Cancer by Elisa Moreno-Palacios, Elsa Delgado, Javier De Santiago and Ignacio Zapardiel Chapter 15 Adenocarcinoma of the Endometrium — The Art of Its Diagnosis by Manoel Afonso Guimarães Gonçalves and Fernando Anschau Preface Gynecologic cancers include malignancies of the female genital tract involving the vulva, vagina, cervix, uterus, fallopian tubes or ovaries. In the USA, 98,280 women had gynecological cancers in 2015, and 30,440 died of these cancers. World wide, the number of women who had cancers of the female genital tract was 1,085,900, in 2012 and the number of deaths was 417,600. Cancers of the uterus, cervix and ovary are most common. Widespread screening with the Pap test has allowed physicians to find per-cancerous changes in the cervix and vagina. This has assisted in identifying some invasive cancers early. Multidisciplinary team of experts includes specialists in medical oncology, gynecologic oncology, radiology, urology, radiotherapy, and surgery who work together to determine the best treatment approach for the patient. Recent progress in the development of new surgical techniques has transformed the treatment of gynecologic cancers, resulting in greater surgical precision and fewer complications. In addition targeted adjuvant therapy has become useful in improving the oncologic outcome of patients with these cancers. Bo Chapter 1 Role of BRCA1 in Breast Cancer Metastasis S. Satheesh Kumar, K.H. Sreelatha, Revathy Nadhan and Priya Srinivas Additional information is available at the end of the chapter http://dx.doi.org/10.5772/60787 Abstract The role of BRCA1 in breast cancer metastasis is a less explored area that might have importance in increased aggressiveness of BRCA1 defective triple negative cancers. The possible influence of BRCA1 on apico basal polarity and ezrin, radixin and meosin (ERM) proteins are discussed in this review as a reason for cell metastasis. This might help in developing antimetastatic drugs that could help for better prognosis in BRCA1 defective breast cancers. Keywords: BRCA1, ezrin, radixin, moesin, apicobasal polarity 1. Introduction Breast cancer is the second largest cancer and the fifth major cause of death. There are many factors involved in breast cancer development and metastasis. Among the tumor suppressors that play a critical role in hereditary breast cancers, BRCA1 mutations are highly frequent, whereas loss of BRCA1 expression by promoter hyper methylation or allelic loss has frequently been noted in sporadic breast cancer [1, 2]. Mutation or loss of the functional BRCA1 expression in breast cancer is usually accompanied with TP53 mutations, ER/PR/HER2 negativity, and loss of ATM/CHK2, which, in turn, leads to a highly aggressive basal phenotype, which clearly possesses a therapeutic challenge [2, 3]. Specific malignant changes caused by BRCA1 muta‐ tions in the breast and the ovary remain a mystery till date.
The list of books you might like
